Clinical trial No longer in our active list Observational Ages 3 and up

Evaluating long-term development in children with Pyridoxine-Dependent Epilepsy

Official title: Standardized Evaluation of Long-term Neurocognitive Development of Children from Age 3 with Pyridoxine Dependent Epilepsy by Antiquitine Deficiency

Run by University Hospital, Angers · NCT06054347 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is trying to see how children over 3 years old with Pyridoxine-Dependent Epilepsy develop their thinking and daily living skills over time.

Quick facts

Study typeObservational
Ages3 Years and up
SexAll
Enrollment30 (estimated)
SponsorUniversity Hospital, Angers
Government
Locations12 sites (Angers and 11 other locations)
Trial IDNCT06054347 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are children aged 3 years and older diagnosed with Pyridoxine-Dependent Epilepsy due to a genetic mutation in the ALDH7A1 gene.

Probably not a fit

Patients who do not understand the French language may not benefit from this study due to the language requirements for participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the long-term neurocognitive development of children over the age of 3 who have Pyridoxine-Dependent Epilepsy due to antiquitine deficiency. Utilizing the Vineland II scale, the study will gather data through a semi-structured questionnaire completed by parents, providing insights into the patients' cognitive abilities and daily living skills. The research seeks to standardize the evaluation of cognitive development in this rare condition, especially in light of recent dietary recommendations that may influence outcomes.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and management of neurodevelopmental outcomes in children with Pyridoxine-Dependent Epilepsy.

How similar studies have gone: Very few studies have evaluated the cognitive development of these patients in a standardized way, making this approach relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age above 3 years old
* Pyridoxine dependent epilepsy genetic diagnosis (mutation in ALDH7A1 gene)
* No objection of the patient or his legal representatives.

Exclusion Criteria:

* Poor understanding of French language.

Where it's running

  • CHU Angers
    Angers, France
    Recruiting
  • CHRU Morvan
    Brest, France
    Recruiting
  • CHU d'Estaing
    Clermont-Ferrand, France
    Recruiting
  • Hôpital Bicêtre
    Le Kremlin-Bicêtre, France
    Recruiting
  • Hôpital Jeanne de Flandre
    Lille, France
    Recruiting
  • Hôpital de la Timone-Enfants
    Marseille, France
    Recruiting
Show 6 more locations
  • CHU Gui de Chautiac
    Montpeliier, France
    Recruiting
  • Hôpital Necker-Enfants malades
    Paris, France
    Recruiting
  • CHU Toulouse
    Toulouse, France
    Recruiting
  • Hôpital Clocheville
    Tours, France
    Recruiting
  • Centre Hospitalier Universitaire de Besançon
    Besançon, France
    Not yet recruiting
  • Centre Hospitalier Saint Nazaire
    Saint-Nazaire, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.